RxDoctor Payments Data

Rex Evans, PA

Physician Assistant · du Bois, PANPI 1215927512

Payments from drug & device makers

$2,756in general payments, 2019–2025

Across 173 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$690
  • AbbVie$439
  • Pfizer$287
  • Lilly USA, LLC$186
  • Boston Scientific$147
  • GSK$121
  • plus $886 from 19 others

What the payments were for

  • Food & beverage$2,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,756 in reported general payments places this provider in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$47,021
Medicare patients
181
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$90,127
EliquisApixaban65$69,049
OzempicSemaglutide21$37,008
TrulicityDulaglutide12$30,590
RybelsusSemaglutide23$27,046
MyrbetriqMirabegron17$13,731
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,052
Levothyroxine Sodium375$4,068
Atorvastatin Calcium256$3,768
Metoprolol Succinate169$3,305
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,810
Rosuvastatin Calcium184$2,517
Potassium Chloride79$2,512
Losartan Potassium184$2,314
Omega-3 Acid Ethyl Esters15$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$53$90,12767 claims
PfizerEliquis$287$69,04965 claims
Novo NordiskOzempic, Rybelsus$690$64,05444 claims
Lilly USA, LLCTrulicity$186$30,59012 claims
Astellas Pharma US IncMyrbetriq$44$13,73117 claims
AbbVieSynthroid$439$1,14122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →